% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hohberg:864751,
      author       = {Hohberg, Melanie and Kobe, Carsten and Krapf, Philipp and
                      Täger, Philipp and Hammes, Jochen and Dietlein, Felix and
                      Zlatopolskiy, Boris D. and Endepols, Heike and Wild, Markus
                      and Neubauer, Stephan and Heidenreich, Axel and Neumaier,
                      Bernd and Drzezga, Alexander and Dietlein, Markus},
      title        = {{B}iodistribution and radiation dosimetry of
                      [18{F}]-{JK}-{PSMA}-7 as a novel prostate-specific membrane
                      antigen-specific ligand for {PET}/{CT} imaging of prostate
                      cancer},
      journal      = {EJNMMI Research},
      volume       = {9},
      number       = {1},
      issn         = {2191-219X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {FZJ-2019-04418},
      pages        = {66},
      year         = {2019},
      abstract     = {Aim We investigated the whole-body distribution and the
                      radiation dosimetry of [18F]-JK-PSMA-7, a novel 18F-labeled
                      PSMA-ligand for PET/CT imaging of prostate cancer.MethodsTen
                      patients with prostate cancer and biochemical recurrence or
                      radiologic evidence of metastatic diseases were examined
                      with 329–384 MBq (mean 359 ± 17 MBq) [18F]-JK-PSMA-7.
                      Eight sequential positron emission tomography (PET) scans
                      were acquired from 20 min to 3 h after injection with
                      IRB approval. The kidneys, liver, lungs, spleen, and
                      salivary glands were segmented into volumes of interest
                      using the QDOSE dosimetry software suite (ABX-CRO, Germany).
                      Absorbed and effective dose were calculated using the
                      ICRP-endorsed IDAC 1.0 package. The absorbed dose of the
                      salivary glands was determined using the spherical model of
                      OLINDA 1.1. PSMA-positive lesions were evaluated separately.
                      Quantitative assessment of the uptake in suspicious lesions
                      was performed by analysis of maximum (max) and peak SUV
                      values. The gluteus maximus muscle (SUVmean) served as a
                      reference region for the calculation of tumor-to-background
                      ratios (TBR’s).ResultsPhysiologic radiotracer accumulation
                      was observed in the salivary and lacrimal glands, liver,
                      spleen, and intestines, in a pattern resembling the
                      distribution known from other PSMA-tracers with excretion
                      via urinary and biliary pathways. The effective dose from
                      [18F]-JK-PSMA-7 for the whole body was calculated to be
                      1.09E−02 mGy/MBq. The highest radiation dose was
                      observed in the kidneys (1.76E−01 mGy/MBq), followed by
                      liver (7.61E−02 mGy/MBq), salivary glands
                      (4.68E−02 mGy/MBq), spleen (1.89E−02 mGy/MBq), and
                      lungs (1.10E-2 mGy/MBq). No adverse effects of tracer
                      injection were observed. Six out of ten patients were scored
                      as PSMA-positive. A total of 18 suspicious lesions were
                      analyzed, which included six bone lesions, nine lymph nodes,
                      and three local lesions within the prostate fossa. The
                      values for the SUVmax and SUVpeak in the PSMA-positive
                      lesions increased until 60 min p.i. and remained at this
                      intensity in the PET/CT scans until 140 min. In the period
                      between 170 and 200 min after injection, a further
                      significant increase in SUVmax and SUVpeak within the
                      PSMA-positive lesions was observed.ConclusionsThe highest
                      TBR of [18F]-JK-PSMA-7 was found 3 h after injection. From
                      the kinetically collected data, it can be concluded that
                      this trend may also continue in the further course. The
                      start of the PET/CT acquisition should be chosen as late as
                      possible. The high uptake in suspicious lesions in terms of
                      absolute SUVmax and relative TBR values indicates
                      potentially high sensitivity of the tracer for detection of
                      prostate cancer manifestations.},
      cin          = {INM-5 / INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31346821},
      UT           = {WOS:000477581200003},
      doi          = {10.1186/s13550-019-0540-7},
      url          = {https://juser.fz-juelich.de/record/864751},
}